Cargando…
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations b...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Endocrine Society
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008669/ https://www.ncbi.nlm.nih.gov/pubmed/36740965 http://dx.doi.org/10.3803/EnM.2022.1642 |